- Home
- EBON vs NRXP Comparison
EBON vs NRXP Comparison
Compare EBON & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBON
- NRXP
- Stock Information
- Founded
- EBON 2010
- NRXP 2015
- Country
- EBON China
- NRXP United States
- Employees
- EBON N/A
- NRXP N/A
- Industry
- EBON Semiconductors
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- EBON Technology
- NRXP Health Care
- Exchange
- EBON Nasdaq
- NRXP Nasdaq
- Market Cap
- EBON 25.3M
- NRXP 32.6M
- IPO Year
- EBON 2020
- NRXP N/A
- Fundamental
- Price
- EBON $4.67
- NRXP $3.27
- Analyst Decision
- EBON
- NRXP Strong Buy
- Analyst Count
- EBON 0
- NRXP 4
- Target Price
- EBON N/A
- NRXP $28.50
- AVG Volume (30 Days)
- EBON 17.0K
- NRXP 215.7K
- Earning Date
- EBON 08-22-2025
- NRXP 08-13-2025
- Dividend Yield
- EBON N/A
- NRXP N/A
- EPS Growth
- EBON N/A
- NRXP N/A
- EPS
- EBON N/A
- NRXP N/A
- Revenue
- EBON $5,868,771.00
- NRXP N/A
- Revenue This Year
- EBON N/A
- NRXP N/A
- Revenue Next Year
- EBON N/A
- NRXP N/A
- P/E Ratio
- EBON N/A
- NRXP N/A
- Revenue Growth
- EBON 20.88
- NRXP N/A
- 52 Week Low
- EBON $3.00
- NRXP $1.10
- 52 Week High
- EBON $10.94
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- EBON 75.89
- NRXP 53.62
- Support Level
- EBON $3.28
- NRXP $2.90
- Resistance Level
- EBON $3.49
- NRXP $3.53
- Average True Range (ATR)
- EBON 0.31
- NRXP 0.20
- MACD
- EBON 0.09
- NRXP -0.04
- Stochastic Oscillator
- EBON 95.54
- NRXP 58.73
About EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.